Share on StockTwits

Illumina (NASDAQ:ILMN) Director A Blaine Bowman sold 5,000 shares of the company’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $179.67, for a total transaction of $898,350.00. Following the transaction, the director now directly owns 12,722 shares in the company, valued at approximately $2,285,762. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Illumina (NASDAQ:ILMN) traded down 1.08% on Wednesday, hitting $177.78. 1,178,291 shares of the company’s stock traded hands. Illumina has a 1-year low of $72.77 and a 1-year high of $185.00. The stock has a 50-day moving average of $170.1 and a 200-day moving average of $161.7. The company has a market cap of $24.782 billion and a price-to-earnings ratio of 120.06.

Illumina (NASDAQ:ILMN) last released its earnings data on Wednesday, July 23rd. The company reported $0.57 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.50 by $0.07. The company had revenue of $448.00 million for the quarter, compared to the consensus estimate of $426.50 million. During the same quarter in the prior year, the company posted $0.43 earnings per share. The company’s quarterly revenue was up 29.5% on a year-over-year basis. Analysts expect that Illumina will post $2.29 EPS for the current fiscal year.

ILMN has been the subject of a number of recent research reports. Analysts at Wedbush upgraded shares of Illumina from a “neutral” rating to an “outperform” rating in a research note on Wednesday, August 20th. They now have a $200.00 price target on the stock, up previously from $165.00. Separately, analysts at Stifel Nicolaus initiated coverage on shares of Illumina in a research note on Monday, August 11th. They set a “buy” rating and a $200.00 price target on the stock. Finally, analysts at Goldman Sachs raised their price target on shares of Illumina from $184.00 to $187.00 in a research note on Tuesday, August 5th. Four equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. Illumina presently has an average rating of “Buy” and an average target price of $178.92.

Illumina, Inc (NASDAQ:ILMN) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.